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always be replicated with inbred ani-
mal models in a regulated environment,
or (3) the methodology in the model
studies or subsequent human trials was
flawed leading to systematic bias (van
der Worp et al., 2010). The challenge in
developing any new therapy for human
diseases involves the careful selection
of a suitable preclinical model(s) to be
used and well-defined human subjects
to be evaluated. Although such issues
cannot be ignored, the identification of
a relevant animal model for a human
disease can prove invaluable for study-
ing disease mechanisms and for devel-
oping and screening new treatments.
The discoveries made in humans,
rats, and mice with AA over the past 20
years led to the understanding just how
complex its genetics, molecular mechan-
isms, and its molecular pathways are
(Carroll et al., 2002; Subramanya et al.,
2010) in regulating its susceptibility,
progression, and resolution (Sundberg
et al., 2003, 2004; Petukhova et al.,
2010; John et al., 2011). Autoimmunity
in humans and other mammals have
many biological and genetic features
that share many common regulatory
pathways and provide valid insights
(Sundberg and Schofield, 2009). Though
the AA models are not perfect represen-
tations of human AA, the fundamental
concepts of AA in rodents and humans
have proven remarkably similar thus so
far. By integrating findings from multiple
sources, great advances will continue to
assist in developing safe and effective
treatments for human and animal dis-
eases including AA.
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TO THE EDITOR
Thymic stromal lymphopoietin (TSLP)
is a key keratinocyte (KC)-derived
cytokine involved in the pathogenesis
of atopic diseases, including atopic
dermatitis (AD) (Liu et al., 2007; Ziegler
and Artis, 2010). Its expression was
found to be increased in skin KCs from
AD patients (Soumelis et al., 2002). We
(Li et al., 2005), and others (Yoo et al.,
2005) have shown that transgenic mice
overexpressing TSLP in KCs develop an
AD-like syndrome, indicating that TSLP
expression is sufficient to initiate
AD-like inflammatory responses. MoreAbbreviations: AD, atopic dermatitis; CT, control; TSLP, thymic stromal lymphopoietin
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recently, we reported that topical
application of the low-calcemic analog
of vitamin D3 (MC903; calcipotriol)
triggers a mouse AD (Li et al., 2006),
which is mediated by induced
keratinocytic TSLP (Li et al., 2009),
as TSLPep/ mice in which TSLP is
ablated selectively in KCs failed to
develop AD. These studies have high-
lighted a critical role for keratinocytic
TSLP in AD pathogenesis, yet, how
TSLP expression is regulated remains
to be investigated. Studies have sug-
gested that TSLP could be regulated at
the transcriptional level by nuclear
receptor signaling (i.e., VD3, retinoid
acids, glucocorticoids, and their recep-
tors) as well as by nuclear factor-kB
signaling ((Li et al., 2005, 2006; Lee
and Ziegler, 2007; Surjit et al., 2011),
and our unpublished data). However,
post-transcriptional regulation of TSLP
expression remains unexplored.
The RNase III enzyme Dicer is
essential for processing pre-miRNAs
into mature, functional miRNAs, which
are capable of post-transcriptional gene
regulation by binding to their target
mRNAs, leading to mRNA degradation
or/and suppression of translation. A
critical role for Dicer has been shown
during mammalian skin development
(Andl et al., 2006; Yi et al., 2006).
However, evidence implicating miR-
NAs expressed in adult KCs in the
pathogenesis of inflammatory skin dis-
eases (e.g., AD) is still lacking.
To investigate the possible involve-
ment of keratinocytic miRNAs in AD
pathogenesis, we generated Diceriep/
mutant mice with induced ablation
of Dicer in epidermal KCs (called
hereafter MT), by tamoxifen injection
to K14-CreERT2tg/0/DicerL3/L3 mice ob-
tained by breeding of DicerL3/L3 mice
(Cobb et al., 2006) with K14-CreERT2tg/0
transgenic mice (Li et al., 2000, 2005)
(Supplementary Figure S1 online).
Tamoxifen-injected K14-CreERT20/0/
DicerL3/L3 littermate mice were used
as control (CT). MT mice did not exhibit
apparent skin abnormalities up to 9
months after Dicer ablation. Histologi-
cal analyses performed at 4–8 weeks
and at 9 months after Dicer ablation did
not reveal obvious modification in
skin morphology (Figure 2a and
data not shown). Therefore, adult skin
homeostasis (in an unchallenged situa-
tion) does not seem to be obviously
impaired in Diceriep/ mice, which
may reflect a different requirement of
keratinocytic Dicer in developmental
(Andl et al., 2006; Yi et al., 2006) and
adult stages.
We then subjected CT and MT mice
(4 weeks after tamoxifen injection)
to topical MC903 treatment on ears
(Li et al., 2006, 2009), to investigate
(i) MC903-induced TSLP production in
the skin; and (ii) TSLP-mediated AD
development in these mice. Analyses of
ears at day 2 (D2) (with MC903
application at D1) or at D4 (with
MC903 application at D1 and D2)
showed that both TSLP transcript
(Figure 1a) and protein (Figure 1b)
levels were higher in MC903-treated
MT compared with MC903-treated CT
skin. Immunohistochemical analyses
confirmed an enhanced TSLP produc-
tion in MC903-treated MT epidermal
KCs (Figure 1c).
We next treated CT and MT mice
continuously with MC903 (every other
day, starting at D1), to induce a
TSLP-mediated AD phenotype. At D8,
MC903-treated MT ears were more red,
scaly, and swollen compared with
MC903-treated CT ears. At D12, a time
when AD appearance was clearly
seen in MC903-treated CT skin, the
MC903-treated MT ears exhibited a
much more heavily inflamed skin with
lesions (data not shown). Histological
analyses at D8 and D12 showed that
upon MC903 application, MT mice
developed a more severe skin inflam-
mation (Figure 2a), with heavily infil-
trated eosinophils (Figure 2b), CD4þ
T cell and mast cells (data not shown)
in the dermis, as well as enhanced
epidermal hyperplasia (Figure 2a).
RT-PCR analyses at D12 revealed
that MC903-induced cytokines were
further increased in MC903-treated
MT skin (Figure 2c): (a) Th2 cytokines
(IL4 and IL13), eosinophil-attractant
chemokine (eotaxin-2), and chemo-
kine receptor (CCR3), which have been
previously demonstrated to be fully
TS
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Figure 1. Increased thymic stromal lymphopoietin (TSLP) expression in MC903-treated Diceriep/ skin. (a) Thymic stromal lymphopoietin (TSLP) RNA
levels in ears, and (b) TSLP protein levels in ear extract at day 2 (D2) and D4 from control (CT) and Diceriep/ mutant (MT) mice, topically treated with ethanol
(EtOH, as vehicle control) or MC903 (1 nmol per day and per ear). Error bars indicate s.e.m. (nX3). (c) Immunohistochemical (IHC) staining of TSLP on ear
sections from MC903 topically treated CT (left panel) and MT (right panel) mice at D4 (with MC903 application at D1 and D2, 1 nmol per day and per ear).
Methods are described in Supplementary Material online. White dashed lines indicate the dermal/epidermal junction. Yellow corresponds to staining of
antibody, whereas blue corresponds to DAPI staining of nuclei. Bar¼ 50 mm.
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TSLP-dependent (Li et al., 2009), were
all significantly increased; (b) IL6, IL10,
and MCP2, which are partially TSLP-
dependent (Li et al., 2009), showed a
tendency to increase (the statistic anal-
yses did not reach significance). The
Th1 cytokine IFN-g, which is TSLP-
independent (Li et al., 2009), was also
elevated in MC903-treated MT skin.
Similar results were obtained by
RT-PCR analyses of skin samples at
D8 (data not shown). Of note, RT-PCR
analyses of these cytokines and chemo-
kines at D2 showed no difference
between MC903-treated CT and MT
mice (Supplementary Figure S2 online),
whereas TSLP expression was signifi-
cantly elevated in MT at this stage
(Figure 1a), suggesting that the
enhanced TSLP production in MT
mice was indeed an early event.
Furthermore, total serum IgE was higher
in MT than in CT mice upon MC903
treatment (Figure 2d). Taken together,
these results indicate that MC903 treat-
ment induces aggravated AD skin
inflammation in Diceriep/ mice.
In conclusion, we show here that
tamoxifen-induced ablation of Dicer
from mouse epidermal KCs results in
an aggravated MC903-induced AD,
accompanied by an elevation of TSLP
production by KCs. We also observed
that, upon topical treatment of dibutyl
phthalate, which was shown to induce
keratinocytic TSLP (Larson et al., 2010),
Diceriep/ MT skin had increased TSLP
production (Supplementary Figure S3
online). These results highlight the
implication of keratinocytic miRNA in
the pathogenesis of AD, through mod-
ulating the production of key cytokines
such as TSLP. Interestingly, evidence for
the involvement of miRNAs in regulat-
ing TSLP expression was recently
shown in gut epithelium (Biton et al.,
2011). Identifying miRNA(s) implicated
in regulating TSLP expression in the
skin and other epithelia will be of great
interest for elucidating the regulation of
this key cytokine, and for developing
new therapeutic approaches for AD and
other atopic diseases. The MC903-
induced AD mouse model should
provide an easy method by which
to screen for miRNA factors in AD
pathogenesis.
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TO THE EDITOR
Pemphigus is a rare autoimmune
blistering disease characterized by high
levels of antibodies against the epider-
mal attachment components, desmo-
glein1 (Dsg-1) and desmoglein3 (Dsg-3;
Amagai, 1999). Intravenous Ig (IVIg)
reduces the levels of these antibodies,
as well as clinical manifestations of
pemphigus, but its mechanism of action
is unknown (Czernik et al., 2008).
There is emerging evidence that pem-
phigus antibodies can cause keratino-
cyte apoptosis and contribute to
acantholysis (Arredondo et al., 2005; Li
et al., 2009; Schmidt and Waschke,
2009). Inhibitors of apoptotic proteins
(IAPs) can target the caspases, and
increases in their levels lead to resistance
to apoptosis (Schimmer, 2004). Antia-
poptotic effect of IVIg on keratinocytes is
well known in disorders such as toxic
epidermal necrolysis (Viard et al., 1998).
Our goal in this study was to determine
whether IAP levels change in sera during
IVIg therapy as a possible mechanism of
suppression of acantholysis.
We measured three IAPs (survivin,
livin, and X-linked IAP (XIAP)) in sera of
seven patients with active pemphigus
(five pemphigus vulgaris and two
pemphigus foliaceus) before and after
treatment with 10% IVIg (Gamunex,
Talecris Biotherapeutics, Durham, NC).
Average age of the patients was 59
(45–74) years. Each course of IVIg
consisted of four cycles, administered
every 2 weeks. Each cycle consisted of
400 mg kg1 per day infused slowly for
5 days. In four patients, IVIg was
administered together with 50–200 mg
per day of oral cyclophosphamide.
All patients were under treatment with
prednisone (20–80 mg per day) before
IVIg therapy. Sera were collected
before treatment, 1 and 2 weeks after
the first and 1 and 4 weeks after the
fourth IVIg cycle. All patients gave
written informed consent according to
the Declaration of Helsinki Principles,
and the study was approved by the
New York University Institutional
Review Board. Serum levels of inter-
cellular IgG antibodies were measured
by indirect immunofluorescence using
esophagus of rhesus monkey as the
substrate. Skin cryosections were incu-
bated with serial serum dilutions of
1:10 to 1:1,280. Goat anti-human
IgG-FITC was used as the secondary
antibody and slides were analyzed
with an epiluminescence microscope.
Anti-Dsg-1 and anti-Dsg-3 antibodies
were measured by ELISA, using a kit
from MBL International, Woburn, MA,
and monoclonal mouse anti-human
IgG4 antibodies (GeneTex, Irvine,
CA) with the technique described
previously (Green and Bystryn, 2008).
Disease severity was measured using
a score described earlier (Lolis et al.,
2011). For quantitative measurement of
IAPs, ELISA kits from R&D Systems,
Minneapolis, MN were used according
to the manufacturer’s instructions.
Serum survivin, livin, and XIAP
were measured in 31 healthy indivi-
duals, and the average levels were
40.1 pg ml1 (SD¼±8.4), 26.2 pg ml1
(±14.4), and 0.9 mg ml1 (±0.29),
respectively. Pretreatment levels of
XIAP and livin in pemphigus patients
(Table 1) were not significantly different
from those of healthy individuals. Survivin
Abbreviations: Dsg-1, desmoglein1; IAP, inhibitors of apoptotic proteins; IVIg, intravenous Ig; XIAP,
X-linked inhibitor of apoptotic proteins
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